Get started
Ekso Bionics Holdings, Inc.Ekso Bionics Holdings, Inc.Ekso Bionics Holdings, Inc.

Ekso Bionics Holdings, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

EKSO chart


Full chart

EKSO upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪13.31 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.6539 USD
Net income (FY)
‪−15.20 M‬ USD
Revenue (FY)
‪18.28 M‬ USD
Shares float
‪20.72 M‬
Beta (1Y)
0.89

Employees


Employees (FY)
70
Change (1Y)
−3 −4.11%
Revenue / Employee (1Y)
‪261.13 K‬ USD
Net income / Employee (1Y)
‪−217.11 K‬ USD

About Ekso Bionics Holdings, Inc.


Sector
Health Technology
Industry
Medical Specialties
CEO
Scott Davis
Website
eksobionics.com
Headquarters
San Rafael
Founded
2012
FIGI
BBG002Z0NKK4
Ekso Bionics Holdings, Inc. engages in the design, development and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. It operates through the following segments: EksoHealth and EksoWorks. The EksoHealth segment consists of the engineering, manufacture, and sale of exoskeletons for applications in the medical markets. The EksoWorks segment offers exoskeleton devices to allow able-bodied users to perform heavy duty work for extended periods. The company was founded on January 30, 2012 and is headquartered in San Rafael, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

EKSO news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of EKSO is 0.6100 USD — it has increased by 4.29% in the past 24 hours. Watch Ekso Bionics Holdings, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Ekso Bionics Holdings, Inc. stocks are traded under the ticker EKSO.
EKSO stock has risen by 6.89% compared to the previous week, the month change is a −13.69% fall, over the last year Ekso Bionics Holdings, Inc. has showed a −64.33% decrease.
We've gathered analysts' opinions on Ekso Bionics Holdings, Inc. future price: according to them, EKSO price has a max estimate of 9.00 USD and a min estimate of 2.00 USD. Watch EKSO chart and read a more detailed Ekso Bionics Holdings, Inc. stock forecast: see what analysts think of Ekso Bionics Holdings, Inc. and suggest that you do with its stocks.
EKSO reached its all-time high on Feb 24, 2014 with the price of 862.8411 USD, and its all-time low was 0.5000 USD and was reached on Dec 12, 2024. View more price dynamics on EKSO chart.
See other stocks reaching their highest and lowest prices.
EKSO stock is 2.98% volatile and has beta coefficient of 0.89. Track Ekso Bionics Holdings, Inc. stock price on the chart and check out the list of the most volatile stocks — is Ekso Bionics Holdings, Inc. there?
Today Ekso Bionics Holdings, Inc. has the market capitalization of ‪13.31 M‬, it has increased by 12.36% over the last week.
Yes, you can track Ekso Bionics Holdings, Inc. financials in yearly and quarterly reports right on TradingView.
Ekso Bionics Holdings, Inc. is going to release the next earnings report on Feb 27, 2025. Keep track of upcoming events with our Earnings Calendar.
EKSO earnings for the last quarter are −0.10 USD per share, whereas the estimation was −0.10 USD resulting in a 4.76% surprise. The estimated earnings for the next quarter are −0.07 USD per share. See more details about Ekso Bionics Holdings, Inc. earnings.
Ekso Bionics Holdings, Inc. revenue for the last quarter amounts to ‪4.13 M‬ USD, despite the estimated figure of ‪5.55 M‬ USD. In the next quarter, revenue is expected to reach ‪5.30 M‬ USD.
EKSO net income for the last quarter is ‪−2.07 M‬ USD, while the quarter before that showed ‪−2.42 M‬ USD of net income which accounts for 14.24% change. Track more Ekso Bionics Holdings, Inc. financial stats to get the full picture.
No, EKSO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 25, 2024, the company has 70.00 employees. See our rating of the largest employees — is Ekso Bionics Holdings, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Ekso Bionics Holdings, Inc. EBITDA is ‪−9.79 M‬ USD, and current EBITDA margin is −73.38%. See more stats in Ekso Bionics Holdings, Inc. financial statements.
Like other stocks, EKSO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Ekso Bionics Holdings, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Ekso Bionics Holdings, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Ekso Bionics Holdings, Inc. stock shows the sell signal. See more of Ekso Bionics Holdings, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.